THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 14, 2006--Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced the pricing of $2.5 billion principal amount of Convertible Senior Notes due 2011 and $2.5 billion principal amount of Convertible Senior Notes due 2013, for an aggregate transaction size of $5 billion. This represents an increase of $1.0 billion from the aggregate transaction size announced Feb. 13, 2006. The notes are being sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
